Email updates

Keep up to date with the latest news and content from Orphanet Journal of Rare Diseases and BioMed Central.

Open Access Research

Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study

Timothy M Cox1*, Dominick Amato2, Carla EM Hollak3, Cecile Luzy4, Mariabeth Silkey4, Ruben Giorgino4, Robert D Steiner5 and for the Miglustat Maintenance Study Group

Author Affiliations

1 University of Cambridge, Addenbrooke's Hospital, Cambridge, UK

2 Mount Sinai Hospital, University of Toronto, Toronto, Canada

3 Academic Medical Centre, Amsterdam, The Netherlands

4 Actelion Pharmaceuticals Ltd, Allschwil, Switzerland

5 Child Development and Rehabilitation Center/Doernbecher Children’s Hospital, Oregon Health & Science University, Portland, OR, USA

For all author emails, please log on.

Orphanet Journal of Rare Diseases 2012, 7:102  doi:10.1186/1750-1172-7-102

Published: 27 December 2012

Abstract

Background

Previous studies have provided equivocal data on the use of miglustat as maintenance therapy in Gaucher disease type 1. We report findings from a clinical trial evaluating the effects of miglustat treatment in patients with stable type 1 Gaucher disease after enzyme therapy.

Methods

Adult type 1 Gaucher disease patients stabilized during at least 3 years of previous enzyme therapy were included in this 2-year, prospective, open-label non-inferiority study. The primary endpoint was percent change from baseline in liver volume. Secondary endpoints included changes in spleen volume, hemoglobin concentration and platelet count.

Results

Forty-two patients were enrolled (mean±SD age, 45.1±12.7 years; previous enzyme therapy duration 9.5±4.0 years). Median (range) exposure to miglustat 100 mg t.i.d. was 658 (3–765) days. Twenty-one patients discontinued treatment prematurely; 13 due to adverse events, principally gastrointestinal. The upper 95% confidence limit of mean percent change in liver volume from baseline to end of treatment was below the non-inferiority margin of 10% (–1.1%; 95%CI −6.0, 3.9%). Mean (95%CI) changes in spleen volume, hemoglobin concentration and platelet count were 102 (24,180) mL, –0.95 (−1.38, –0.53) g/dL and −44.1 (–57.6, –30.7) ×109/L, respectively.

Conclusions

The primary efficacy endpoint was met; overall there was no change in liver volume during 24 months of miglustat therapy. Several patients showed a gradual deterioration in some disease manifestations, suggesting that miglustat could maintain clinical stability, but not in all patients. Miglustat demonstrated a predictable profile of safety and tolerability that was consistent with that reported in previous clinical trials and experience in clinical practice.

Trial registration

Clinicaltrials.gov identifier NCT00319046

Keywords:
Gaucher disease; Miglustat; Enzyme therapy; Maintenance; Efficacy; Safety